Table 3.
Prevalence of mild insomnia and moderate to severe insomnia in patients postpancreaticoduodenectomy.
| Variable | ISI score 8–14 (n = 12) | ISI score ≥ 15 (n = 7) | ||
|---|---|---|---|---|
| Age, mean ± SD | 68.6 ± 9.5 | 61.7 ± 13.2 | ||
| Gender, n (%) | Male | 8 (66.7%) | 5 (71.4%) | |
| Female | 4 (33.3%) | 2 (28.6%) | ||
| BMI, mean ± SD | 27.0 ± 6.4 | 24.4 ± 4.1 | ||
| Smoking, n (%) | 2 (16.7%) | 3 (42.9%) | ||
| Alcohol consumption, n (%) | 2 (16.7%) | 3 (42.9%) | ||
| Caffeine intake, n (%) | 5 (41.7%) | 5 (71.4%) | ||
| Physical activity, n (%) | 8 (66.7%) | 5 (71.4%) | ||
| Comorbidities, n (%) | Diabetes | 5 (41.7%) | 3 (42.9%) | |
| COPD | 0 | 0 (4.5%) | ||
| CVD | 6 (50.0%) | 4 (57.1%) | ||
| CKD | 0 | 1 (14.3%) | ||
| Tumor characteristics, n (%) | Grade | 1 | 1 (8.3%) | 1 (14.3%) |
| 2 | 7 (58.3%) | 6 (85.7%) | ||
| 3 | 4 (33.3%) | 0 | ||
| 4 | 0 | 0 | ||
| T stage | 1 | 0 | 2 (28.6%) | |
| 2 | 9 (75.0%) | 4 (57.1%) | ||
| 3 | 3 (25.0%) | 1 (34.3%) | ||
| 4 | 0 | 0 | ||
| N stage | 0 | 3 (25.0%) | 2 (28.6%) | |
| 1 | 5 (41.7%) | 4 (57.1%) | ||
| 2 | 4 (33.3%) | 1 (14.3%) | ||
| M stage | 0 | 11 (91.7%) | 7 (100.0%) | |
| 1 | 1 (8.3%) | 0 | ||
| Tumor size, mean ± SD | 2.8 ± 1.1 | 2.8 ± 1.4 | ||
| Treatment regimen, n (%) | Adjuvant chemotherapy∗ | 6 (50.0%) | 6 (85.7%) | |
| Neoadjuvant chemotherapy | 0 | 1 (14.3%) | ||
| Adjuvant radiotherapy | 0 | 0 | ||
| Neoadjuvant radiotherapy | 0 | 0 | ||
| No chemotherapy or radiotherapy | 6 (50.0%) | 0 | ||
| All-cause mortality, n (%) | 1 (8.3%) | 0 | ||
BMI: body mass index; COPD: chronic obstructive pulmonary disease; CVD: cardiovascular disease; CKD: chronic kidney disease; ISI: Insomnia Severity Index; PSQI: Pittsburgh Sleep Quality Index. ∗Significance at p < 0.05; ∗∗significance at p < 0.01.